Uniting Preclinical Innovation, GMP-Ready Manufacturing & Regulatory Clarity to Accelerate Scalable, Clinically Successful iPSC Therapies Across Parkinson's, Diabetes, Oncology & More
The 6th iPSC Drug Development Summit was the only meeting exclusively focused on advancing iPSC-based cell therapies, end-to-end. It brought together leaders such as Aspen Neuroscience, BlueRock Therapeutics, and Vertex Pharmaceuticals, who are building programs today, spanning discovery, preclinical development, process development, CMC, and regulatory strategy. By joining the summit, attendees learned how iPSC therapies are being designed for scale and clinical success from the very beginning.
After years of uncertainty, the field is re-emerging on the 20th anniversary of iPSC technology, with stronger clinical data than ever before. The room heard directly from companies driving this progress, including Century Therapeutics, advancing its Type 1 diabetes program into the clinic, and BlueRock Therapeutics, generating positive data as it moves into Phase III.
With investment at its strongest point in years, and the likes of Aspen Neuroscience and Century Therapeutics securing $100 million-plus in funding rounds, the focus has shifted decisively from promise to performance. This summit was designed to help teams understand what “right execution” looks like today, with the invest panel and roundtable delving into how those decisions will shape the next decade of iPSC therapy development.
Companies in the field are now committed to moving into the clinic and focused on delivering to patients. As attention shifts toward scalability, quality, and regulatory alignment, this summit provided the forum for biopharma, investment, and solution providers to unite and accelerate the transition from research to real-world therapies.
If you’re serious about iPSC drug development, this was a must-attend meeting!
I enjoyed all the speakers, great agenda, and the ease of connecting with people. The speed networking session was good!
Director PSC Biology, BlueRock Therapeutics
The talks were high quality and well organized. It was valuable to hear diverse perspectives on iPSC applications, and the networking opportunities stood out.
Professor Medical & Health, Harvard Medical School
I thought it was a nice mix of vendors and key stakeholders from companies of interest in the field. Good discussions and the right amount of time set aside for socializing in the vendor area, lunches, and at posters. Overall nice atmosphere.
Director, Voyager Therapeutics
Key Topics for 2026
Explore the 2026 Event Guide
- 25+ Industry-leading speakers
- End-to-end coverage of iPSC drug development
- 2 dedicated tracks on preclinical development, and process development and CMC
- Unrivaled networking opportunities with clinical companies securing investments
- See why this is the must-attend meeting for iPSC development
2026 Speakers Included:
2026 Partners
Attending Companies Included
Explore the 2026 Agenda
See where the bottlenecks really are and how teams are solving them.
This agenda goes beyond theory to highlight the decisions shaping real iPSC programs, from line selection and genome integrity to late stage scale up, comparability, and regulatory confidence.
Partner With Us
Shape the discussion at the point where priorities are being set.
Partnering with the summit gives you a unique opportunity to position your organization at the heart of the iPSC community, build meaningful connections, and become the go-to partner for the iPSC community.
Join the iPSC Community
Connect with a field that has moved past experimentation.
Meet a focused community of leaders working through the realities of clinical translation, manufacturing scale, and regulatory alignment. Biopharma and academics can attend for free!